Liver Disease Information
In Your Area
Contact us for more information and questions about the Research Awards Program.
American Liver Foundation
39 Broadway, Suite 2700
New York, New York 10006
Roger L. Jenkins, MD Postdoctoral Research Fellowship
Pennsylvania State University, State College, Pennsylvania
Targeting PPARβ/δ to Inhibit Hepatic Inflammation
Liver cancer is the most rapidly increasing type of cancer. Increased inflammation can modulate hepatocarcinogenesis whereas anti-inflammatory compounds can inhibit liver cancer. Targeting peroxisome proliferator-activated receptor β/δ (PPARβ/δ) can modulate cellular homeostasis and result in epigenetic activities such as inhibition of expression of proinflammatory cytokines. Dr. Palkar hypothesizes that PPARβ/δ attenuates hepatic inflammation by modulating NF-κB dependent inflammatory signaling in Kupffer cells. Preliminary results indicate that PPARβ/δ protects against hepatotoxicity, likely by direct interaction of PPARβ/δ with NF-κB and inhibition of pro-inflammatory signaling. To examine this hypothesis, Dr. Palkar will use transgenic mice with DNA binding mutations on PPARβ/δ in Kupffer cells. Mice will be injected with lipopolysaccharide ± the highly specific PPARβ/δ agonist, GW0742. Markers of inflammation will be evaluated and chromatin immunoprecipitation assays performed to provide direct mechanistic evidence for how PPARβ/δ can attenuate hepatic inflammation. The proposed studies using the mouse models will determine if epigenetic modulation of PPARβ/δ can protect against hepatic inflammation in vivo. Results from Dr. Palkar’s proposal will also determine if PPARβ/δ can be used as an anti-inflammatory molecular target and as an alternative strategy for preventing and treating inflammatory liver diseases.
© Copyright 2017 American Liver Foundation. All Rights Reserved. The American Liver Foundation is included in CharityWatch’s 2016 list of Top-Rated Charities and is a Member of the World Hepatitis Alliance.